In the original publication of this manuscript [1], Fig. 1 contained a typographical error (‘Metabolic’ incorrectly written as ‘Metabolig’). The caption for Fig. 1 also contained typographical errors; “… regulated via O2-independent mechanisms.” should be instead have read “… regulated by O2-dependent mechanisms.”, and the caption should refer to 25 years and not 15 years. Figure 1 and its caption have now been corrected and are shown below.
Fig. 1
Schematic representation of the effects of intratumoral hypoxia in human diseases. a Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric protein that consists of a constitutively expressed HIF-1β subunit and a HIF-1α subunit regulated by O2-dependent mechanisms. Activated HIF-1 transcription factor binds to the hypoxia response elements (HRE) to induce transcription of, among others, target genes involved in angiogenesis, glucose metabolism, cell proliferation/survival, and invasion/metastasis. b Schematic representation of the number of scientific papers related to HIF-1, published in the last 25 years, and the relative diseases
×
In addition, the following sentences have been adjusted to remove ambiguity and correct the record:
‘Background’ section, “Hypoxia Inducible Factor-1 (HIF-1), is an α/β heterodimeric transcription factor that controls multiple oxygen-sensitive genes. In 1995 Semenza identified HIF-1α as a basic-helix-loop-helix-PAS heterodimer regulated by cellular oxygen tension” has been corrected to “In 1995, Semenza identified the Hypoxia Inducible Factor-1 (HIF-1) as a basic-helix-loop-helix-PAS α/β heterodimeric transcription factor regulated by cellular oxygen tension.”
‘Background’ section, “… as evidenced by the increased number of papers published on this topic in the last 15 years” has been corrected to “… as evidenced by the increased number of papers published on this topic in the last 25 years.”
Anzeige
The authors sincerely apologize for the inconvenience caused to the readers. The original article has been updated.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.
Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.
Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
